NASDAQ:AXDXAccelerate Diagnostics Stock Price, Forecast & News

Accelerate Diagnostics' stock was trading at $10.61 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, AXDX stock has increased by 54.1% and is now trading at $16.35.
View which stocks have been most impacted by Coronavirus.

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Accelerate Diagnostics in the last year. There are currently 1 sell rating and 2 buy ratings for the stock, resulting in a consensus recommendation of "Hold."
View analyst ratings for Accelerate Diagnostics.

Accelerate Diagnostics is scheduled to release its next quarterly earnings announcement on Thursday, November 5th 2020.
View our earnings forecast for Accelerate Diagnostics.

Accelerate Diagnostics Inc (NASDAQ:AXDX) released its quarterly earnings results on Thursday, May, 7th. The medical research company reported ($0.39) earnings per share (EPS) for the quarter, meeting the Thomson Reuters' consensus estimate of ($0.39). The medical research company earned $2.34 million during the quarter, compared to analysts' expectations of $2.40 million. Accelerate Diagnostics had a negative net margin of 803.60% and a negative return on equity of 5,681.44%.
View Accelerate Diagnostics' earnings history.

3 brokers have issued 1-year target prices for Accelerate Diagnostics' shares. Their forecasts range from $16.00 to $20.00. On average, they anticipate Accelerate Diagnostics' stock price to reach $18.00 in the next year. This suggests a possible upside of 10.1% from the stock's current price.
View analysts' price targets for Accelerate Diagnostics.

News coverage about AXDX stock has been trending very positive recently, InfoTrie Sentiment Analysis reports. The research group rates the sentiment of media coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Accelerate Diagnostics earned a media sentiment score of 3.2 on InfoTrie's scale. They also gave press coverage about the medical research company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an effect on the company's share price in the immediate future.
View the latest news about Accelerate Diagnostics.

Accelerate Diagnostics saw a decline in short interest in July. As of July 31st, there was short interest totaling 15,760,000 shares, a decline of 8.9% from the July 15th total of 17,300,000 shares. Based on an average daily volume of 497,200 shares, the short-interest ratio is presently 31.7 days. Approximately 56.3% of the company's shares are sold short.
View Accelerate Diagnostics' Short Interest.

Some companies that are related to Accelerate Diagnostics include Coherent (COHR), Horiba (HRIBF), Quanterix (QTRX), Pacific Biosciences of California (PACB), Fluidigm (FLDM), Harvard Bioscience (HBIO), Eyepoint Pharmaceuticals (EYPT), BioNano Genomics (BNGO), Precipio (PRPO), HTG Molecular Diagnostics (HTGM), Aethlon Medical (AEMD), Scientific Industries (SCND), Pressure Biosciences (PBIO), Arrayit (ARYC) and PositiveID (PSID).
View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Accelerate Diagnostics investors own include Himax Technologies (HIMX), Magnachip Semiconductor (MX), Fluidigm (FLDM), Universal Display (OLED), Gilead Sciences (GILD), BIOLASE (BIOL), Alibaba Group (BABA), AbbVie (ABBV), AT&T (T) and Exelixis (EXEL).

Accelerate Diagnostics trades on the NASDAQ under the ticker symbol "AXDX."

Accelerate Diagnostics' stock is owned by a variety of retail and institutional investors. Top institutional investors include Cannell Peter B & Co. Inc. (2.02%), Chicago Capital LLC (1.37%), UBS Group AG (0.15%), Swiss National Bank (0.12%), Mitsubishi UFJ Kokusai Asset Management Co. Ltd. (0.07%) and New York State Common Retirement Fund (0.05%). Company insiders that own Accelerate Diagnostics stock include Jack W Schuler, John Patience, Romney Humphries, Steven Reichling and Thomas D Brown.
View institutional ownership trends for Accelerate Diagnostics.

AXDX stock was sold by a variety of institutional investors in the last quarter, including Chicago Capital LLC, and UBS Group AG.
View insider buying and selling activity for Accelerate Diagnostics.

AXDX stock was bought by a variety of institutional investors in the last quarter, including Cannell Peter B & Co. Inc., Russell Investments Group Ltd., Mitsubishi UFJ Kokusai Asset Management Co. Ltd., SG Americas Securities LLC, Principal Financial Group Inc., Virtu Financial LLC, Swiss National Bank, and New York State Common Retirement Fund. Company insiders that have bought Accelerate Diagnostics stock in the last two years include Jack W Schuler, John Patience, Steven Reichling, and Thomas D Brown.
View insider buying and selling activity for Accelerate Diagnostics.

Shares of AXDX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of AXDX stock can currently be purchased for approximately $16.35.

Accelerate Diagnostics has a market capitalization of $903.66 million and generates $9.30 million in revenue each year. The medical research company earns $-84,310,000.00 in net income (profit) each year or ($1.55) on an earnings per share basis. Accelerate Diagnostics employs 287 workers across the globe.

The official website for Accelerate Diagnostics is acceleratediagnostics.com.

Accelerate Diagnostics' mailing address is 3950 South Country Club Suite 470, Tucson AZ, 85714. The medical research company can be reached via phone at 520-365-3100 or via email at [email protected]